Ravicti (Glycerol Phenylbutyrate) Patent Expiration, LOE Window & CMS Spending
Ravicti (Glycerol Phenylbutyrate) by Amgen: FDA Orange Book LOE 2030-09-22, 0 AB generics, $344.1M 2024 CMS Part D & Medicaid spend, and $1,597 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amgen |
| FDA Application & Pathway | N203284 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-09-22 |
| Orange Book Patents (*PED Extensions) | 14 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $344.1M |
| 2024 Medicare Part D Spend | $79.5M |
| 2024 Medicaid Spend | $264.6M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,597 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.